Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.74 |
| ▸ | SHBG | P04278 | 3/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxendolone SCHEMBL12826307 | 1.00 | PGR (0.74) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| Oxendolone SCHEMBL1650323 | 1.00 | PGR (0.74) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| Oxendolone SCHEMBL10380170 | 1.00 | PGR (0.74) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| SCHEMBL10380864 | 0.91 | PGR (0.66) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| SCHEMBL10624478 | 0.86 | ALDH1A1 (0.72) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| SCHEMBL17209910 | 0.86 | SHBG (0.72) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| SCHEMBL17078378 | 0.85 | PGR (1.00) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| SCHEMBL21010519 | 0.85 | PGR (1.00) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| SCHEMBL4660380 | 0.85 | PGR (1.00) | PGRSHBGSERPINA6ALDH1A1SLC22A1 | |
| SCHEMBL14870642 | 0.85 | PGR (1.00) | PGRSHBGSERPINA6ALDH1A1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525938-B1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20250319216-A1 | RADIOPHARMCEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2025-10-16 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2025-08-21 | — | — | US | claimed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | claimed |
| EP-4525938-A1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | Bayer Aktiengesellschaft (DE) | 2025-03-26 | — | — | EP | claimed |
| WO-2024091572-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | VERADERMICS INCORPORATED (US) | 2024-05-02 | — | — | WO | claimed |
| EP-4305206-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | Koninklijke Philips N.V. (NL) | 2024-01-17 | — | — | EP | claimed |
| US-11850306-B2 | Method for drying hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose | UPM-KYMMENE CORPORATION (FI) | 2023-12-26 | — | — | US | claimed |
| WO-2023222557-A1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-23 | — | — | WO | claimed |
| EP-0138029-B1 | PHARMACEUTICAL COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 1992-01-02 | — | — | EP | claimed |
| US-4973469-A | ACTIVE MATERIAL ADSORBED ON CROSSLINKED POLYMER, INACTIVE MATERIAL CONTROLS SOLUBILITY | ELAN CORPORATION, PLC (IE) | 1990-11-27 | — | — | US | claimed |
| EP-0232155-A2 | Drug delivery system | ELAN CORPORATION PLC (IE) | 1987-08-12 | — | — | EP | claimed |
| US-4657901-A | MIXTURE OF OXENDOLONE, KERATOLYTIC AGENT AND CARRIER | Sheiseido Company, Ltd. (JP) | 1987-04-14 | — | — | US | claimed |
| EP-0072662-B1 | AQUEOUS SUSPENSION OF OXENDOLONE | Takeda Chemical Industries, Ltd. (JP) | 1985-05-22 | — | — | EP | claimed |
| EP-0138029-A2 | Pharmaceutical composition | Takeda Chemical Industries, Ltd. (JP) | 1985-04-24 | — | — | EP | claimed |
| US-4462996-A | WITH NONIONIC SURFACTANT AND P-HYDROXYBENZOIC ACID ESTER; ANTIANDROGENS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-07-31 | — | — | US | claimed |
| EP-0095944-A2 | Anti-androgenic preparation for oral cavity administration | Takeda Chemical Industries, Ltd. (JP) | 1983-12-07 | — | — | EP | claimed |
| EP-0072662-A2 | Aqueous suspension of oxendolone | Takeda Chemical Industries, Ltd. (JP) | 1983-02-23 | — | — | EP | claimed |
| US-4298538-A | 16-Dimethylaminomethylene-3-methoxy-1,3,5-(10)-estratrien-17-one, a process for the preparation thereof and its use as a preparative intermediate | SCHERING, AKTIENGESELLSCHAFT (DE) | 1981-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | PGR 3978/4885SHBG 3358/4885SERPINA6 3185/4885 |
| US-20250319216-A1 | RADIOPHARMCEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | KLK3, FOLH1, PSMA2 | PGR 773/4885SHBG 4/4885SERPINA6 347/4885 |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | TGFB1, TGFB2, SMAD3 | PGR 2891/4885SHBG 55/4885SERPINA6 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.